Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury

Novo Nordisk

Status: Completed

Conditions: Trauma; Acquired Bleeding Disorder

Treatments: Drug: activated recombinant human factor VII

Study type: Observational

Funder types: Industry

Identifiers

NCT00124293

F7CBI-1587

Details and patient eligibility

About

This study is conducted in North America. The purpose of this study is to evaluate the occurrence and severity of bleeding in brain injury and to identify important safety issues following traumatic brain injury.

Enrollment: 63 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Ages Eligible for Study: 18 Years - 85 Years

Trial design

63 participants in 1 patient group

Factor VII

Treatment:

Drug: activated recombinant human factor VII